IDEAYA Biosciences R&D Day Event: Where RAS Meets MTAP/CDKN2A: Targeting Dual Dependencies in PDAC and Beyond
| DATE: | November 16, 2026 |
|---|---|
| TIME: | 5:00 PM GMT |
| LOCATION: | The Savoy Hotel, Strand, London WC2R 0EZ, United Kingdom |
About The Event
Join IDEAYA Biosciences for an R&D Day in London with key opinion leader Dr. Frank McCormick, Ph.D. (UCSF Helen Diller Family Comprehensive Cancer Center), who will outline the company’s current clinical development strategy in MTAP/CDKN2A and KRAS solid tumors, with a particular focus on pancreatic cancer (PDAC).
UPDATED AGENDA:
The event will provide an overview of:
- IDEAYA’s precision medicine pipeline and new preclinical data on rational combinations targeting tumor heterogeneity and adaptive plasticity in PDAC and other priority solid tumors
- RAS progress: breakthroughs, emerging data, and future challenges
- IDEAYA’s approach in RAS-driven cancers: IDE892 (PRMT5) in RAS-mutant PDAC, CDKN2A in RAS-mutant cancers, and IDE574 to intercept epigenetic alterations that drive resistance
- Upcoming milestones in RAS/MTAP
A live question and answer session will follow the formal presentations.